Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 807-811

  Yang, Deok Hwan ^a   Kim, Won Seog ^b   Kim, Seok Jin ^b   Kim, Jin Seok ^c   Kwak, Jae Yong ^d   Chung, Joo Seop ^e   Oh, Sung Yong ^f   Suh, Cheolwon ^g   Lee, Je Jung ^a  

^a Chonnam National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yonsei University   (South Korea)

^d Chonbuk National University Medical School   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f Dong A University   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

Author keywords

90Y ibritumomab tiuxetan; bulky disease; diffuse large B cell lymphoma; limited stage

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN YTTRIUM 90; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG TOXICITY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PILOT PROJECTS; PREDNISOLONE; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 84859957788     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.635857     Document Type: Article

References (24)

1. F isher RI, Miller TP, O' C onnor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221-236.
2. Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004;22:2982-2984. (Pubitemid 41103709)
3. R eyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-1205. (Pubitemid 40397261)
4. M iller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26. (Pubitemid 28304493)
5. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861 (Pubitemid 46348180)
6. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26: 2258-2263.
7. P freundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
8. M udie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006;24:1568-1574. (Pubitemid 46638780)
9. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-115. (Pubitemid 43939037)
10. Sacchi S, Marcheselli L, Bari A, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 2008;93:1335-1342.
11. J uweid ME. Radioimmunotherapy of B-cell non-Hodgkin' s lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43:1507-1529. (Pubitemid 35285877)
12. P ress OW. Evidence mounts for the efficacy of radio immunotherapy for B-cell lymphomas. J Clin Oncol 2008;26:5147-5150.
13. H agenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90Y)-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol a2005;16:786-792. (Pubitemid 40767101)
14. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
15. S harkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009;113:3891-3895.
16. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
17. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-3038. (Pubitemid 41103714)
18. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-2804. (Pubitemid 46179470)
19. N ieder C, Licht T, Andratschke N, et al. Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treat Rev 2003;29:11-19. (Pubitemid 36395519)
20. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29-36. (Pubitemid 47026815)
21. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787-792. (Pubitemid 350002878)
22. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435-444.
23. Z inzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769-773. (Pubitemid 351461050)
24. Z inzani PL, Rossi G, Franceschetti S, et al. Phase II trial of shortcourse R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010;16:3998-4004.